ONCY: 溶瘤生物科技

ONCY新闻

• 14:09 Oncolytics launches phase 2 colorectal cancer study REO 033
• 14:05 Oncolytics to wind down GOBLET study, focus on U.S. registration
• 14:33 Oncolytics Biotech股价飙升，FDA授予快速通道资格认定
• 14:33 Oncolytics Biotech stock soars after FDA grants Fast Track Designation
• 16:53 Pelareorep-atezolizumab联合疗法在肛门癌治疗中显示出有前景的结果
• 16:52 Pelareorep-atezolizumab shows promising results in anal cancer
• 14:17 Oncolytics Biotech计划将公司注册地从加拿大迁至内华达州
• 14:15 Oncolytics Biotech plans to shift incorporation from Canada to Nevada
• 14:07 Oncolytics Biotech files patent application to extend pelareorep protection
• 14:08 Oncolytics Biotech expands GI cancer advisory board with three experts
• 14:27 Oncolytics reports 33% response rate in hard-to-treat colorectal cancer
• 23:05 Oncolytics Biotech reschedules shareholder vote on U.S. domicile move
• 14:35 Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
• 21:33 Oncolytics Biotech reschedules special meeting due to government shutdown
• 17:00 All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
• 14:05 Oncolytics Biotech to launch pivotal pancreatic cancer trial in 2026
• 13:05 Oncolytics Biotech forms GI cancer scientific advisory board
• 11:37 Oncolytics reports doubled response rate in anal cancer treatment
• 11:04 Pelareorep shows promising results in colorectal cancer treatment
• 14:43 Onc stock hits 52-week high at 309.25 USD
• 13:31 BeOne Medicines stock hits 52-week high at 304.0 USD
• 13:31 BeOne Medicines stock reaches 52-week high at 294.41 USD
• 16:46 BeOne Medicines stock price target raised to $349 from $311 at RBC Capital
• 12:37 Oncolytics Biotech reports positive biomarker data for pelareorep